Trillium Therapeutics Inchares (NASDAQ:TRIL) Has Decline in Shorts

October 13, 2018 - By Ash

The stock of Trillium Therapeutics Inchares (NASDAQ:TRIL) registered a decrease of 14.93% in short interest. TRIL’s total short interest was 112,800 shares in October as published by FINRA. Its down 14.93% from 132,600 shares, reported previously. With 52,500 shares average volume, it will take short sellers 2 days to cover their TRIL’s short positions.

The stock increased 4.84% or $0.18 during the last trading session, reaching $3.9. About 68,870 shares traded. Trillium Therapeutics Inc. (NASDAQ:TRIL) has risen 29.70% since October 13, 2017 and is uptrending. It has outperformed by 14.08% the S&P500.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $56.65 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

More notable recent Trillium Therapeutics Inc. (NASDAQ:TRIL) news were published by: Seekingalpha.com which released: “Trillium’s TTI-621 shows encouraging action in early-stage studies” on September 28, 2018, also Benzinga.com with their article: “45 Biggest Movers From Yesterday” published on October 05, 2018, Seekingalpha.com published: “Trillium Therapeutics Updates On Lead Lymphoma Trials” on October 04, 2018. More interesting news about Trillium Therapeutics Inc. (NASDAQ:TRIL) were released by: Benzinga.com and their article: “32 Stocks Moving In Thursday’s Mid-Day Session” published on October 04, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares” with publication date: October 10, 2018.

Trillium Therapeutics Inc. (NASDAQ:TRIL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>